About: Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines
Creator	Perlman, Stanley Qin, Chuan Baric, Ralph Subbarao, Kanta Black, Steven Perlman, S Black, S Martin, S Lambert, Paul-Henri Ambrosino, Donna Andersen, Svein Baric, R Chen, R Cramer, Jakob Graham, B Graham, Barney Dekker, Cornelia Pollard, A Pollard, Andrew Didierlaurent, A Chen, Robert Subbarao, K Didierlaurent, Arnaud Martin, Samantha Molrine, Deborah Picard-Fraser, Philip Qin, C Ambrosino, D Andersen, S Cramer, J Dekker, C Lambert, P-H Molrine, D Picard-Fraser, P
Source	Elsevier; Medline; PMC
abstract	A novel coronavirus (CoV), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 in Wuhan, China and has since spread as a global pandemic. Safe and effective vaccines are thus urgently needed to reduce the significant morbidity and mortality of Coronavirus Disease 2019 (COVID-19) disease and ease the major economic impact. There has been an unprecedented rapid response by vaccine developers with now over one hundred vaccine candidates in development and at least six having reached clinical trials. However, a major challenge during rapid development is to avoid safety issues both by thoughtful vaccine design and by thorough evaluation in a timely manner. A syndrome of “disease enhancement” has been reported in the past for a few viral vaccines where those immunized suffered increased severity or death when they later encountered the virus or were found to have an increased frequency of infection. Animal models allowed scientists to determine the underlying mechanism for the former in the case of Respiratory Syncytial virus (RSV) vaccine and have been utilized to design and screen new RSV vaccine candidates. Because some Middle East respiratory syndrome (MERS) and SARS-CoV-1 vaccines have shown evidence of disease enhancement in some animal models, this is a particular concern for SARS-CoV-2 vaccines. To address this challenge, the Coalition for Epidemic Preparedness Innovations (CEPI) and the Brighton Collaboration (BC) Safety Platform for Emergency vACcines (SPEAC) convened a scientific working meeting on March 12 and 13, 2020 of experts in the field of vaccine immunology and coronaviruses to consider what vaccine designs could reduce safety concerns and how animal models and immunological assessments in early clinical trials can help to assess the risk. This report summarizes the evidence presented and provides considerations for safety assessment of COVID-19 vaccine candidates in accelerated vaccine development.
has issue date	2020-05-25(xsd:dateTime)
bibo:doi	10.1016/j.vaccine.2020.05.064
bibo:pmid	32507409
has license	no-cc
sha1sum (hex)	b84aee5e817cdb14e899d8571321d3f5db29852b
schema:url	https://doi.org/10.1016/j.vaccine.2020.05.064
resource representing a document's title	Consensus Summary Report for CEPI/BC March 12-13, 2020 Meeting: Assessment of Risk of Disease Enhancement with COVID-19 Vaccines
has PubMed Central identifier	PMC7247514
has PubMed identifier	32507409
schema:publication	Vaccine
resource representing a document's body	covid:b84aee5e817cdb14e899d8571321d3f5db29852b#body_text
is schema:about of	named entity 'needed' named entity 'response' named entity 'However' named entity 'encountered' named entity 'March 12' named entity 'Vaccines' named entity 'disease' named entity 'avoid' named entity 'Animal models' named entity 'suffered' named entity 'Respiratory' named entity 'global' named entity 'Epidemic' named entity 'immunology' named entity 'Wuhan' named entity 'vaccine' named entity 'development' named entity 'accelerated' named entity 'immunological' named entity 'Innovations' named entity 'summarizes' named entity 'Coronavirus' named entity 'animal models' named entity 'infection' named entity 'scientific' named entity 'COVID-19' named entity 'COVID-19' named entity 'Meeting' named entity 'morbidity' named entity 'vaccine' named entity 'RSV' named entity 'vACcines' named entity 'vaccine' named entity 'SARS-CoV-1' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'China' named entity 'Respiratory Syncytial virus' named entity 'disease enhancement' named entity 'vaccines' named entity 'vaccine' named entity 'vaccine design' named entity 'clinical trials' named entity 'immunization' named entity 'macaques' named entity 'SARS-CoV-2' named entity 'infection' named entity 'isotypes'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software